The Chronic Kidney Disease Solution Reviews: Shelly Manning Releases Book Audit Independent Content Review, 89-Day Customer Support Analysis Published Together

BOISE, Idaho · October 18, 2026 – Blue Heron Health News has released the first formal audit of The Chronic Kidney Disease Solution, combining an independent program content review with findings from an 89-day customer support analysis and a comprehensive sweep of unauthorized digital distribution of the program since its launch. The company said publishing all three data sets together was a deliberate choice: each answers a question the others leave open, and releasing them in the same document removes the incentive to present any one figure selectively.

The Chronic Kidney Disease Solution book is a 123-page digital guide authored by Shelly Manning, a natural health researcher the company describes as having more than 40 years in clinical practice. The guide presents a sequential 3-Phase protocol for dietary and lifestyle support of kidney health and is sold as a one-time digital download at $49 through ClickBank, the company’s authorized payment processor. The company reports that 47,300 copies have been distributed since launch, that 1,423 verified reader reviews have been submitted averaging 5.0 stars, and that the 60-day refund rate for the audit period was 4.1%.

The October 2026 audit draws on four sources: an independent content review completed for program version CKDS-2610-01 by Pacific Research Documentation Services, Inc.; an 89-day customer support analysis covering July 21 through October 18, 2026; a digital piracy and unauthorized distribution sweep completed on October 16, 2026; and verified reader review data aggregated through October 15, 2026.

“Most readers come to me after their nephrologist has delivered what feels like a verdict — that their kidneys will continue to decline and that eventually dialysis is the destination. What I have found over more than four decades is that kidneys are far more responsive to targeted dietary and lifestyle intervention than the current standard of care fully acknowledges. The 400-plus studies I compiled for this program are the same peer-reviewed literature published in the same journals your nephrologist reads. We are applying that research in a comprehensive, sequential protocol — addressing gut health, inflammation, and cellular repair in the correct order — rather than waiting passively for pharmaceutical options to slow what is already slowing.”

— Shelly Manning, Natural Health Researcher & Author, The Chronic Kidney Disease Solution

First Program Audit: Key Figures at a Glance

In the 89-day support analysis, the company’s team reviewed 1,614 inbound contacts opened between July 21 and October 18, 2026. Of those, 1,317 were matched to a purchase record in the company’s fulfillment system and 297, representing 18.4% of the period’s caseload, were not. The refund rate among verified purchases for the same period was 4.1%. In the verified reader survey, 94.2% of 5,642 respondents rated their overall experience as satisfied or very satisfied.

On unauthorized distribution, the October 16 sweep identified 277 unauthorized listings across six platforms and 14 look-alike domains. The company filed DMCA takedown notices on all 277 listings. As of October 17, 2026, 202 listings (72.9%) had been removed or suspended; 75 remained live. Registrar or hosting complaints were filed against all 14 look-alike domains. A counterfeit and impersonation submission was filed with the Federal Trade Commission under reference FTC-261014.

What Drove the October Audit: Three Support Themes in the Trailing 89 Days

The company categorized the 1,317 matched contacts by primary subject and released the three largest groups. It said none of the three involved a confirmed safety event connected to the program’s content.

Theme One: Download and Access Issues

The largest group comprised purchasers who could not locate the program after completing their order. In the majority of these cases, agents established that ClickBank’s post-purchase confirmation email — which carries the download link — had been filtered to spam or junk folders by the recipient’s email provider before it could be opened. Resolution involved resending the ClickBank receipt along with a direct member-login link. The company said it subsequently added a plain-text confirmation backup email to all new orders and updated the ClickBank order-confirmation page with explicit instructions to check spam folders, in an effort to reduce this contact category in future audit periods.

Theme Two: Protocol and Program Questions

The second-largest group was readers at Stage 3 and Stage 4 of CKD who contacted support for clarification on stage-appropriate food quantities, identification of the Phase 2 natural compounds, and interpretation of their own lab results within the context of the program’s tracking sheets. The company said this volume of protocol questions reflected a reader base that was actively engaging with the material rather than passively consuming it, and that it does not categorize such contacts as complaints. To address the volume, Blue Heron Health News published a supplemental “Stage-by-Stage Q&A” document in October 2026, made available at no additional cost to all verified purchasers through the member portal. The company noted that all lab interpretation questions were handled by directing readers to discuss their results with their nephrologist, consistent with the program’s consistent instruction that medical decisions remain with the treating physician.

Theme Three: Billing and Refund Inquiries

The third group consisted of contacts related to order recognition and the 60-day money-back guarantee. A subset came from purchasers who did not recognize the “CLICKBANK” billing descriptor on their payment statement and contacted support believing the charge was unauthorized. The company said all official purchases of The Chronic Kidney Disease Solution are processed through ClickBank and that the CLICKBANK descriptor is expected on any legitimate charge; it said it is updating post-purchase communications to set this expectation before a statement arrives. A smaller subset involved purchasers who had downloaded the program from a third-party file-sharing site and then sought a refund from Blue Heron Health News; because those transactions did not originate with the company, they were not eligible for the guarantee, and those contacts were logged separately as unauthorized distribution matters. Refund requests from verified purchasers within the 60-day window were processed within three business days through ClickBank’s standard channel; the company reported no verified purchaser was refused a refund during the audit period.

Unauthorized Distribution Sweep: October 16, 2026

As a digital-only product, The Chronic Kidney Disease Solution faces an unauthorized distribution challenge that differs from physical consumer goods: pirated PDF copies, bootleg download bundles, and look-alike sites created to intercept prospective buyers. The company conducted its October 16 sweep across six platforms, submitting DMCA takedown requests where available and marketplace policy reports where DMCA is not the applicable mechanism.

The sweep also identified 14 standalone websites that copied the Blue Heron Health News brand name, product images, or checkout page layout. The company said at least three of these sites were collecting payment directly — not routing to ClickBank — meaning purchasers on those sites received no guarantee coverage, potentially received no product, and had no recourse through the company. Registrar or hosting complaints were filed against all 14 domains. The company said it cannot confirm the content, completeness, or accuracy of any copy of the program distributed through unauthorized channels, and that the version history and supplement documents available to verified purchasers through the member portal are not included in files distributed on third-party networks.

False statements observed in the same sweep period included invented claims that the program had received endorsement from the American Kidney Fund or the National Kidney Foundation — endorsements the company said it has never received and has not sought — and fabricated reader-outcome statistics attributed to named individuals. The company said those claims are actionable under FTC guidelines on testimonials and endorsements and are being pursued as a separate enforcement matter.

Independent Content Review: Program Version CKDS-2610-01

Pacific Research Documentation Services, Inc., which the company describes as holding ISO/IEC 17065:2012 certification (Cert. No. 2247.03), conducted a review of program version CKDS-2610-01 completed October 9, 2026, covering six panels: citation accuracy cross-referenced against PubMed and MEDLINE; protocol sequence logic for the 3-Phase framework; medical safety language for FDA and FTC compliance; content integrity for consistency between cited sources and the claims drawn from them; formatting and accessibility against WCAG 2.1 AA; and editorial independence for undisclosed conflicts of interest. The company said the program version passed all six panels and that the content review found a citation accuracy rate of 98.7% across the 400-plus references included in the guide.

The company said it conducts a content review with each substantive update to the program and that version CKDS-2610-01 is the current edition at the time of this report’s publication. The full review certificate is available to verified purchasers on request through the company’s support channel.

Program content review is a quality and accuracy standard, not a regulatory approval. The company does not present the Pacific Research Documentation Services review as an endorsement of the program’s health claims by any government agency or independent clinical body.

Is The Chronic Kidney Disease Solution a Legitimate Program? The Four Records a Buyer Can Check

Online searches for verification of the program have grown alongside its distribution volume, and the company frames its answer around four records a buyer can inspect independently.

A single authorized purchase channel. The company sells The Chronic Kidney Disease Solution only through its official sales page at blueheronhealthnews.com, processed through ClickBank. The company has no resellers on Amazon, eBay, Scribd, Telegram, or any other platform. Any listing on those platforms was not created by the company. All authorized purchases carry the CLICKBANK descriptor on the payment statement.

A published program description and table of contents. The 123-page guide is described by the company as organized into a Phase 1 gut and inflammation reset (Weeks 1–12), a Phase 2 metabolic repair framework (Months 4–9), and a Phase 3 cellular support protocol (Month 10 onward), alongside a phase roadmap, stage-appropriate food selection guides, optional supplement protocols, and lab tracking sheets. The company has posted the full table of contents on its official sales page.

An independent content review of the current program version. Pacific Research Documentation Services, Inc. reviewed version CKDS-2610-01 against six quality panels and reported passage on all six. The review certificate is available on request to verified purchasers through the support channel.

A 60-day money-back guarantee on official purchases. Every purchase made through the authorized ClickBank checkout is covered by a full refund for 60 days. The company said no verified purchaser was refused a refund during the audit period. The guarantee does not cover copies obtained through third-party sites, file-sharing networks, or any channel other than the official ClickBank checkout.

The 3-Phase Protocol: Scientific and Regulatory Context

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) estimates that 37 million adults in the United States — approximately 15% of the adult population — have chronic kidney disease, and that most people with CKD do not know they have it. The NIDDK states that CKD can be managed through blood pressure control, blood sugar management in people with diabetes, and a kidney-friendly diet, and recommends that people with CKD work closely with their health care team, including a registered dietitian. The NIDDK does not endorse any specific dietary supplement or natural protocol for the prevention or treatment of CKD, and no government agency has evaluated The Chronic Kidney Disease Solution for safety or efficacy.

The following sections describe the scientific and regulatory context for each element of the program as presented by the company. Reference information in this section is drawn from government and peer-reviewed sources and is general nutritional and research information; it is not individual medical advice and does not evaluate the program specifically.

Phase 1 — Gut and Inflammation Reset (Weeks 1–12)

The NIDDK publishes eating guidance for people with CKD that emphasizes reducing sodium, phosphorus, potassium, and protein in stage-appropriate amounts and choosing heart-healthy foods. The institute recommends working with a registered renal dietitian to develop an individualized eating plan and states that dietary needs change as CKD progresses. The institute does not specifically address modulation of the gut microbiome as a CKD management strategy in its consumer-facing guidance.

The scientific concept on which Phase 1 is built — the gut-kidney axis — describes a bidirectional relationship between the intestinal microbiome and kidney function. A 2024 review in Kidney International Supplements characterized the gut-kidney axis as “an emerging therapeutic target” and noted that observational data linking gut dysbiosis to elevated uremic toxin levels (particularly indoxyl sulfate and p-cresyl sulfate) are consistent across cohort studies. The same review described the intervention evidence as “promising but not yet sufficient to support specific clinical recommendations beyond standard CKD dietary advice,” noting that most fiber and prebiotic trials in CKD populations enrolled fewer than 100 participants and followed participants for 8–12 weeks. The company said Phase 1 draws on this literature to construct a gut-rebalancing dietary framework, but it has not conducted independent clinical trials of the protocol.

The company’s food selection guides are described as stage-stratified, with different food allowances for Stage 2–3 readers than for Stage 4 readers, reflecting the more restrictive potassium and phosphorus limits that apply at later disease stages. The company recommends that readers share the Phase 1 food list with their renal dietitian before beginning.

Potassium and phosphorus caution. Several foods associated with microbiome-supporting fiber — including legumes, whole grains, and some fruits and vegetables — are also high in potassium or phosphorus, which may need to be limited depending on CKD stage and individual lab values. The company said the phase-specific food guides account for these restrictions; this publication has not independently verified that all food selections in the guide fall within the limits recommended by the NIDDK for each stage category.

Phase 2 — Metabolic Repair Protocol (Months 4–9)

Phase 2 introduces what the company describes as “natural compounds for metabolic repair,” with particular focus on mitochondrial support in renal tubular cells. The company has not disclosed the specific compounds in this phase in its public sales materials, describing them collectively as widely available at supplement retailers and individually priced under $10. The company said the selection was guided by 2019–2025 nephrology literature on mitochondrial dysfunction in CKD.

Regarding CoQ10, the most frequently cited mitochondrial compound in the relevant literature: the National Center for Complementary and Integrative Health (NCCIH) states that CoQ10 is found naturally in cells and plays a role in energy production and that people with certain conditions, including heart failure, have been found to have lower CoQ10 blood levels. The center notes that evidence for CoQ10 supplementation is mixed across conditions and that few large, well-designed randomized trials are available. A 2024 review in Kidney International described mitochondrial dysfunction as “increasingly recognized” in CKD and stated that early-phase human data for mitochondria-targeting nutritional interventions “show sufficient promise to warrant larger randomized trials” while explicitly stopping short of clinical recommendations at this stage of the evidence base.

Regarding alpha-lipoic acid, another compound studied in this context: the NCCIH states that alpha-lipoic acid is a compound that acts as an antioxidant, noting that research results in humans are mixed and that most trials have been small. The center advises that alpha-lipoic acid may lower blood sugar and should be used with caution by people already managing blood sugar levels, including the large proportion of CKD patients whose disease is diabetic in origin.

The company said it does not instruct readers to make changes to diabetes or blood pressure medications independently and that Phase 2 supplement additions are presented as optional, not required, components of the protocol.

Phase 3 — The Golden Nugget Protocol (Month 10 Onward)

The company describes Phase 3 as the program’s centerpiece and refers to its central element as “the Golden Nugget Protocol,” a cluster of compounds the company said addresses cellular senescence in nephrons. Cellular senescence — the accumulation of non-dividing, pro-inflammatory cells within kidney tissue — is an active research area in nephrology. The company said it draws on a 2019 pilot clinical trial published in EBioMedicine by Hickson et al. as one supporting reference. That trial enrolled nine participants with diabetic kidney disease and tested dasatinib combined with quercetin; it reported reductions in senescent cell markers but described itself as preliminary. Dasatinib is a prescription tyrosine kinase inhibitor not available without a prescription; quercetin is a flavonoid available as a dietary supplement. The company said the Golden Nugget Protocol uses over-the-counter compounds only, though it does not name them in its public-facing materials.

NAD+ precursors — including nicotinamide riboside and niacin — are also referenced in the cellular repair literature the company cited. A 2023 pilot trial cited in the program’s reference list examined NAD+ precursor supplementation in older adults and reported preliminary tolerability data; the authors described it as hypothesis-generating. The company acknowledged that Phase 3 represents the most emerging segment of the evidence base and that the clinical trial literature at this stage consists primarily of small or early-phase studies.

The Lab Monitoring and Tracking System

The program includes lab tracking sheets designed to help readers record and organize the standard blood and urine tests their nephrology team orders over time. The Kidney Disease: Improving Global Outcomes (KDIGO) organization published updated CKD management guidelines in 2024 recommending monitoring intervals for serum creatinine, eGFR, urine albumin-to-creatinine ratio, potassium, phosphorus, and bicarbonate calibrated to disease stage and trajectory. KDIGO describes regular lab monitoring as standard of care and recommends that patients bring their records to nephrology appointments. The company said its tracking sheets are aligned with KDIGO 2024 monitoring intervals; this publication has not independently verified that alignment. The company explicitly positioned the tracking sheets as a tool for collaborative use with the treating nephrologist, not for self-managed care decisions.

Who Should Consult a Physician or Registered Dietitian Before Using This Program

The program explicitly instructs all readers to remain under the care of a licensed nephrologist and to continue all prescribed medications without independent modification. Beyond the general recommendation, sources cited in this report identify several specific situations that warrant physician or dietitian consultation before beginning any dietary or supplement protocol:

• Stage 4 or Stage 5 CKD: the program’s own disclaimer states that Stage 5 and dialysis patients require a level of medical management beyond the scope of a dietary guide and should not begin this or any natural protocol without nephrologist clearance.
• People taking ACE inhibitors, ARBs, or potassium-sparing diuretics: dietary changes that increase potassium intake may interact with these medications; physician coordination is essential.
• People managing diabetes through insulin or oral agents: compounds in Phase 2 with potential blood-sugar-lowering effects (including alpha-lipoic acid) may require monitoring adjustments.
• People using anticoagulant or antiplatelet medications: some botanical compounds studied in the CKD context have demonstrated potential anticoagulant effects in preclinical models; consultation with the prescribing physician is appropriate before adding any supplement.
• People with a history of hormone-sensitive conditions: the broader natural compound literature includes ingredients with estrogenic activity; relevant compounds should be reviewed with a physician.
• People with known kidney stone history: high-oxalate plant foods common in kidney-health dietary frameworks may be contraindicated in certain stone subtypes.

CKD Background: Disease Burden and Evidence Base

The NIDDK states that CKD is the 9th leading cause of death in the United States and that approximately 2 in 5 adults with severely reduced kidney function do not know they have CKD. The institute states that there is no cure for CKD and that treatment focuses on slowing the progression of kidney damage, usually by controlling the cause. For diabetic kidney disease — the most common CKD etiology in the United States — the NIDDK cites blood sugar management, blood pressure control, and specific approved medications as the evidence-based interventions with demonstrated effect on CKD progression.

The NIDDK does not endorse dietary supplements or natural protocols as treatments for CKD, and none of the peer-reviewed literature cited in this report tested The Chronic Kidney Disease Solution as a whole program. The studies referenced describe research on individual dietary patterns, food components, or compounds at specific doses — conditions that may differ substantially from how those same elements appear in the program. Individual ingredient or dietary-component studies do not constitute evidence that the program as a whole produces the outcomes described in reader testimonials.

The American Kidney Fund states that while diet and lifestyle changes are an important part of CKD management and can help slow disease progression, the degree of benefit varies by individual, disease stage, and cause of CKD, and that no dietary approach should substitute for medical care or prescribed treatment. The company said its program is consistent with this framing and that the guide opens with a statement that it is designed to complement medical care, not to replace it.

Pricing, Guarantee and Where to Buy

The company has maintained the same pricing since launch. As of October 18, 2026, The Chronic Kidney Disease Solution is available as a one-time digital download at $49. There is no subscription, no automatic renewal, and no upsell to a physical product.

The 60-day money-back guarantee covers purchases made through the authorized ClickBank checkout only. The company cannot refund or replace copies obtained through Scribd, Telegram, social media groups, or any third-party site, because it has no record of those transactions. The company said the guarantee window was chosen to allow readers to complete Phase 1 of the protocol (12 weeks) before the window closes for those who begin immediately, though it noted that most measurable lab changes are expected around the three-month mark and beyond.

Summary of Findings: Blue Heron Health News First Program Audit

▸ The company reports 47,300 copies of The Chronic Kidney Disease Solution distributed since launch, with 1,423 verified reader reviews submitted averaging 5.0 stars.

▸ Of 1,614 inbound support contacts in the 89-day audit period, 297 (18.4%) could not be matched to a company purchase record.

▸ The three largest support themes were download and access issues, protocol and program questions, and billing and refund inquiries. The company said none of the three involved a confirmed safety event connected to the program’s content.

▸ The 60-day refund rate for verified purchases in the audit period was 4.1%. The company said no verified purchaser was refused a refund during this period.

▸ The October 16, 2026 unauthorized distribution sweep identified 277 listings across six platforms and 14 look-alike domains; 202 listings (72.9%) were removed or suspended by October 17, 2026.

▸ Pacific Research Documentation Services, Inc. reviewed program version CKDS-2610-01 and reported passage on all six review panels: citation accuracy, protocol sequence logic, medical safety language, content integrity, WCAG 2.1 AA formatting, and editorial independence. The company reported a citation accuracy rate of 98.7%.

▸ The program targets readers at Stage 2–4 CKD; the company explicitly states it is not appropriate for Stage 5 or dialysis patients without nephrologist clearance, and instructs all readers to continue prescribed medications without independent modification.

▸ No government agency has evaluated The Chronic Kidney Disease Solution or the dietary and supplement interventions it describes for the treatment or prevention of CKD.

“We are one company publishing one program, sold through one channel. If a copy didn’t come from that channel, we have no information about its completeness, its version, or whether the member supplements and tracking tools were included. That distinction matters every time someone asks whether the program produced results — because the answer depends entirely on whether they had the complete version.”

— Blue Heron Health News, Program Audit Statement, October 2026

Frequently Asked Questions

Is The Chronic Kidney Disease Solution a legitimate program?

The company sells the program exclusively through its official ClickBank checkout, publishes a full table of contents and program description, had program version CKDS-2610-01 independently reviewed by Pacific Research Documentation Services across six quality panels, and offers a 60-day full refund on all purchases. The program is a dietary and lifestyle guide, not a regulated medical treatment.

Where is the program sold?

According to the company, only through its official sales page at blueheronhealthnews.com, processed through ClickBank. The company has no resellers on Scribd, Amazon, Telegram, Facebook Marketplace, or any other platform. Any listing on those platforms was not created by the company and is not eligible for the guarantee.

What does the independent content review show?

Pacific Research Documentation Services, Inc. reviewed program version CKDS-2610-01 and reported passage on citation accuracy, protocol sequence logic, medical safety language, content integrity, WCAG 2.1 AA formatting, and editorial independence. The company reported a citation accuracy rate of 98.7% across the 400-plus references in the guide. The review certificate is available on request to verified purchasers through the support channel.

Is this program safe for someone on kidney medications?

The program instructs readers to continue all prescribed medications without change, and to involve their nephrologist in any adjustments that become appropriate as kidney markers change. People using ACE inhibitors, ARBs, potassium-sparing diuretics, anticoagulants, or diabetes medications should consult their physician before beginning any dietary or supplement protocol described in the guide.

What is the refund policy?

A 60-day money-back guarantee covers purchases made through the authorized ClickBank checkout. Refund requests from verified purchasers within the 60-day window are processed through ClickBank within three business days; the program is digital, so no return shipment is required.

Why does my statement show “CLICKBANK” rather than Blue Heron Health News?

All authorized purchases are processed through ClickBank, the company’s payment processor. The CLICKBANK descriptor on a payment statement confirms the transaction went through the official channel. If the descriptor shows anything other than CLICKBANK, the charge was placed by an unauthorized source; contact your card issuer to dispute it and report the site to the FTC at reportfraud.ftc.gov.

How quickly do results appear?

The company’s reader outcomes data are non-clinical and self-reported. It reports that readers most frequently notice subjective improvements — sleep, energy, reduced swelling — within the first four weeks, which it attributes to early dietary and microbiome shifts. Measurable lab changes such as eGFR and serum creatinine are described by the company as typically first appearing around the three-month lab draw; full protocol effects in the case histories documented by the company run nine to fifteen months. Individual results vary, and the company does not guarantee specific lab outcomes.

What CKD stages is this program for?

The program targets readers at Stage 2, Stage 3, and Stage 4. The program’s own disclaimer excludes Stage 5 and dialysis patients, stating they require a level of medical management beyond the scope of a dietary protocol and should not begin without direct nephrologist supervision and clearance.

Limitations of This Report

This report relies on figures released by Blue Heron Health News, including the 89-day support analysis, the digital piracy sweep, the content review summary for version CKDS-2610-01, and verified reader review data. None of those figures was independently audited by this publication. The verified reader satisfaction data is self-reported and collected under opt-in conditions; results may not be representative of all purchasers, including those who did not engage with the program, who experienced no improvement, or who did not submit a review. The 4.1% refund rate reflects verified purchases through the authorized channel and does not account for purchasers who obtained the program through unauthorized sources and sought refunds elsewhere.

The independent content review by Pacific Research Documentation Services, Inc. is a program-quality audit; it is not a clinical trial, a regulatory review, or an endorsement of the health claims associated with the program. None of the peer-reviewed research cited in this report evaluated The Chronic Kidney Disease Solution as a complete program. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

References

1. National Institute of Diabetes and Digestive and Kidney Diseases, Chronic Kidney Disease — https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd
2. NIDDK, Eating and Nutrition for Chronic Kidney Disease — https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/eating-nutrition
3. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease, Kidney Int Suppl. 2024;14(1):1–117 — https://kdigo.org/guidelines/ckd-evaluation-and-management/
4. National Center for Complementary and Integrative Health, Coenzyme Q10 — https://www.nccih.nih.gov/health/coenzyme-q10
5. National Center for Complementary and Integrative Health, Alpha-Lipoic Acid — https://www.nccih.nih.gov/health/alpha-lipoic-acid
6. Evenepoel P, et al. The gut-kidney axis and uremic toxins in CKD. Kidney Int Suppl. 2024;14(1):45–52.
7. Hu EA, et al. DASH dietary pattern and CKD incidence: findings from the ARIC Study. Am J Kidney Dis. 2022;80(2):198–207.
8. Galvan DL, et al. Mitochondrial dysfunction in CKD. Kidney International. 2024;105(2):229–240.
9. Hickson LJ, et al. Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in diabetic kidney disease. EBioMedicine. 2019;47:446–456 — https://pubmed.ncbi.nlm.nih.gov/31113755/
10. Zhao J, et al. Prebiotic fiber supplementation and uremic toxin reduction in Stage 3 CKD. J Ren Nutr. 2023;33(5):624–633.
11. American Kidney Fund, Diet and Kidney Disease — https://www.kidneyfund.org/all-about-kidneys/kidney-disease/diet-and-chronic-kidney-disease
12. Levey AS, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737–1749.
13. U.S. Food and Drug Administration, Dietary Supplements — https://www.fda.gov/food/dietary-supplements
14. Federal Trade Commission, ReportFraud — https://reportfraud.ftc.gov/

About Blue Heron Health News

Blue Heron Health News is a natural health publishing company specializing in evidence-based dietary and lifestyle guides for chronic conditions, including kidney disease, blood pressure, blood sugar, and cardiovascular health. The company’s programs are sold exclusively as digital downloads through ClickBank and are backed by a 60-day money-back guarantee on all official purchases. The company does not sell pharmaceutical products and does not accept advertising from supplement manufacturers. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Media Contact

• Publisher: Blue Heron Health News
• Program: The Chronic Kidney Disease Solution
• Author: Shelly Manning, Natural Health Researcher
• Website: blueheronhealthnews.com

The post The Chronic Kidney Disease Solution Reviews: Shelly Manning Releases Book Audit Independent Content Review, 89-Day Customer Support Analysis Published Together appeared first on 24 Health Times.

About The Author

pramanrt